Chang Gong
Breast Tumor Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Breast Tumor Center, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Chang Gong as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:16 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07796880 · Neoadjuvant Culmerciclib Combined With Endocrine Therapy for Hormone Receptor-Positive， Human Epidermal Growth Factor Receptor 2-Negative Breast CancerSun Yat-Sen Memorial Hospital of Sun Yat-Sen University · recruiting · Hormone Receptor-Positive Breast Cancer, HER2 Low Breast Carcinoma, Early-Stage Breast Cancer · principal investigator
- N/ANCT07554781 · A Single-Center, Retrospective Study to Improve the Visibility of Breast Tissue Marker Clips in Breast Tissue and Axillary Lymph Nodes Using the Color Doppler Twinkling ArtifactSun Yat-Sen Memorial Hospital of Sun Yat-Sen University · not yet recruiting · Breast Cancer · study director
- Ph3NCT06404775 · External Mastalgia-oil Versus Oral Tamoxifen in Premenopausal Women with Severe MastalgiaSun Yat-Sen Memorial Hospital of Sun Yat-Sen University · not yet recruiting · Mastalgia · principal investigator
- Ph3NCT06144944 · Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast CancerSun Yat-Sen Memorial Hospital of Sun Yat-Sen University · active not recruiting · Breast Cancer Invasive, Hormone-receptor-positive Breast Cancer, HER2 Low Breast Carcinoma · principal investigator
- N/ANCT05801705 · Comparative Evaluation of Efficacy and Safety of Toremifene, Tamoxifen, and Aromatase Inhibitor Plus Ovarian Function Suppression in Hormone Receptor-Positive Early Breast Cancer Among Non-Low-Risk Premenopausal Women: A Real-World StudySun Yat-Sen Memorial Hospital of Sun Yat-Sen University · unknown · Hormone-receptor-positive Breast Cancer, Premenopausal Breast Cancer, Breast Cancer Patients at Intermediate to High Risk · study chair
- Ph3NCT05165069 · The Efficacy and Safety of Mecobalamin in the Prevention of Capecitabine Induced Hand Foot SyndromeSun Yat-Sen Memorial Hospital of Sun Yat-Sen University · active not recruiting · Hand-foot Syndrome · study chair
Grants
NIH projects from RePORTER, fetched 2026-11-12 11:16 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in breast cancer, ranked by citations from NIH iCite, fetched 2026-11-12 11:16 UTC. The ranking covers the 200 most relevant of 13 PubMed records, and a shared surname and initials can bring in a namesake. All 13 on PubMed
- Phase II study of chidamide in combination with cisplatin in patients with metastatic triple-negative breast cancer.Ann Palliat Med · 202120 citationsRCR 1.0
- 19 citationsRCR 0.7
- 15 citationsRCR 3.1
- Phase II trail of nab-paclitaxel in metastatic breast cancer patients with visceral metastases.BMC Cancer · 202111 citationsRCR 0.6
- Preclinical study and phase 2 trial of neoadjuvant pyrotinib combined with chemotherapy in luminal/HER2-low breast cancer: PILHLE-001 study.Cell Rep Med · 20249 citationsRCR 1.1
- The Effect of Low and High Vacuum Drainage on the Postoperative Drainage of Breast Cancer: Insights from a Prospective, Non-Inferiority, Randomized Clinical Trial.Cancer Manag Res · 20206 citationsRCR 0.4
- 5 citationsRCR 0.9
- 3 citationsRCR 0.6
- 2 citationsRCR 0.1